Quarterly report pursuant to Section 13 or 15(d)

Financial instruments

Financial instruments
6 Months Ended
Jun. 30, 2017
Financial instruments [Abstract]  
Financial instruments

14.Financial Instruments


The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, restricted cash, deposits, accounts payable and accrued liabilities and notes payable. The Company is exposed to risks related to changes in interest rates and management of cash and cash equivalents and short-term investments.


Credit risk


Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and restricted cash. These assets include Canadian dollar and U.S. dollar denominated certificates of deposits, money market accounts and demand deposits. These instruments are maintained at financial institutions in Canada and the United States. Of the amount held on deposit, approximately $0.7 million is covered by the Canada Deposit Insurance Corporation, the Securities Investor Protection Corporation or the United States Federal Deposit Insurance Corporation, leaving approximately $14.2 million at risk at June 30, 2017 should the financial institutions with which these amounts are invested be rendered insolvent. The Company does not consider any of its financial assets to be impaired as of June 30, 2017.


All of the Company’s customers have Moody’s Baa or greater ratings and purchase from the Company under contracts with set prices and payment terms.


Liquidity risk


Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due.


As at June 30, 2017, the Company’s financial liabilities consisted of trade accounts payable and accrued trade and payroll liabilities of $1.369 million which are due within normal trade terms of generally 30 to 60 days, a note payable which will be payable over a period of four years.


On May 27, 2016, we entered into an At Market Issuance Sales Agreement with MLV & Co. LLC and FBR Capital Markets & Co. under which we may, from time to time, issue and sell Common Shares at market prices on the NYSE American or other U.S. market through the distribution agents for aggregate sales proceeds of up to $10,000,000. During 2017, we have sold 1,536,169 Common Shares under the sales agreement at an average price of $0.76 per share for gross proceeds of $1.2 million. After deducting transaction fees and commissions we received net proceeds of $1.1 million.


We made our final contract sale for 2017 in July, which was for 109,000 pounds at $35.35 per pound.  We purchased the pounds delivered for $20.15.   At this point, we therefore do not have any additional contract revenues until next January when we have scheduled deliveries to our customers.  In the interim, we currently have over 160,000 pounds of  uranium at the conversion facility and will continue to produce inventory through the end of the year.  We therefore have a substantial amount of uranium which   can be sold under spot contracts during the latter half of the year if it is advantageous to do so. 

We expect that any major capital projects will be funded by operating cash flow, cash on hand or additional financing as required. If these cash sources are not sufficient, certain capital projects could be delayed, or alternatively we may need to pursue additional debt or equity financing to which there is no assurance that such financing will be available at all or on terms acceptable to us


Sensitivity analysis


The Company has completed a sensitivity analysis to estimate the impact that a change in interest rates would have on the net loss of the Company. This sensitivity analysis shows that a change of +/- 100 basis points in interest rate would have a negligible effect on either the six months ended June 30, 2017 or the comparable six months in 2016. The financial position of the Company may vary at the time that a change in interest rates occurs causing the impact on the Company’s results to differ from that shown above.